Nicorandil analogues containing NO-donor furoxans and related furazans

被引:10
作者
Boschi, D
Cena, C
Di Stilo, A
Fruttero, R
Gasco, A
机构
[1] Dipartimento Sci & Tecnol Farm, I-10125 Turin, Italy
[2] Dipartimento Sci Chim Alimentari Farmaceut Farmac, I-28100 Novara, Italy
关键词
D O I
10.1016/S0968-0896(00)00098-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The synthesis and in vitro vasodilating properties of hybrid compounds in which furoxan (1,2,5-oxadiazole 2-oxide) moieties, endowed with different NO-donor properties, were substituted for the nitroxy function of Nicorandil are reported. The corresponding cyanoguanidine analogues are also considered. This approach has led to a series of vasorelaxing compounds devoid of affinity for K-ATP channels, whose activity is prevalently due to their ability to activate sGC, at the concentrations of the experiments. Related furazan (1,2,5-oxadiazole) derivatives, unable to release nitric oxide were also prepared and studied for control. The amide analogues of Nicorandil display feeble vasorelaxing action not involving the activation of K+ channels, while in the guanidine analogues, this mechanism seems to underlie this action. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1727 / 1732
页数:6
相关论文
共 20 条
[1]   Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes:: Correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies [J].
Atwal, KS ;
Grover, GJ ;
Lodge, NJ ;
Normandin, DE ;
Traeger, SC ;
Sleph, PG ;
Cohen, RB ;
Bryson, CC ;
Dickinson, KEJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (03) :271-275
[2]   Studies on agents with mixed NO-dependent vasodilating and β-blocking activities [J].
Boschi, D ;
Di Stilo, A ;
Cena, C ;
Lolli, M ;
Fruttero, R ;
Gasco, A .
PHARMACEUTICAL RESEARCH, 1997, 14 (12) :1750-1758
[3]  
CALVINO R, 1980, EUR J MED CHEM, V15, P485
[5]   New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities [J].
Di Stilo, A ;
Visentin, S ;
Cena, C ;
Gasco, AM ;
Ermondi, G ;
Gasco, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (27) :5393-5401
[6]   STRUCTURE-ACTIVITY-RELATIONSHIPS OF K+ CHANNEL OPENERS [J].
EDWARDS, G ;
WESTON, AH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (10) :417-422
[7]   AIRWAY PHARMACOLOGY OF THE POTASSIUM CHANNEL OPENER, HOE-234, IN GUINEA-PIGS - INVITRO AND INVIVO STUDIES [J].
ENGLERT, HC ;
WIRTH, K ;
GEHRING, D ;
FURST, U ;
ALBUS, U ;
SCHOLZ, W ;
ROSENKRANZ, B ;
SCHOLKENS, BA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 210 (01) :69-75
[8]  
Evans J M, 1994, Prog Med Chem, V31, P411, DOI 10.1016/S0079-6468(08)70026-2
[9]  
Feelish M, 1996, METHODS NITRIC OXIDE
[10]  
Fruttero R, 1997, FARMACO, V52, P405